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ABSTRACT
Purpose: Melatonin is a neurohormone mainly synthesized in the pineal gland; however, it is also
present in the aqueous humor. One of melatonins’ functions in the eye is the regulation of intraocular
pressure (IOP). Melatonin is known to be sensitive to light. Recently, the photopigment which controls
melatonin synthesis, melanopsin, was found in the crystalline lens. Therefore, light conditions are an
interesting possible way of regulating melatonin levels in the aqueous humor. The current study used
yellow filters, since melanopsin is activated by short wavelength (blue light).
Methods: New Zealand white rabbits were used, divided in two groups, one under controlled 12 h light/
dark cycles, while the rest had their cages encased with a yellow filter (λ 465–480). IOP measurements
were taken every week at the same time before they were anesthetized for aqueous humor extraction.
Results: Keeping the rabbits under the yellow filter resulted in a decrease in IOP up to 43.8 ± 7.8% after
3 weeks. This effect was reversed after the topical application of selective and nonselective melatonin
receptors antagonists, 4PPDOT and luzindole. Also, blocking melanopsin by its antagonist AA92593
under white light condition decreased IOP. Finally, melatonin levels were found significantly higher in
the aqueous humor of rabbits developed under yellow filter compared to controls (37.4 ± 4.2 and
15.3 ± 3.1 ng/ml, respectively).
Conclusion: Yellow filters modulate melatonin levels in the aqueous humor due to deactivating
melanopsin activity. This effect leads to a decrease in IOP mediated by melatonin receptors.
ARTICLE HISTORY
Received 19 October 2018
Revised 10 December 2018
Accepted 7 January 2019
KEYWORDS
Yellow filter; intraocular
pressure; melatonin;
melanopsin
Introduction
Melatonin (N-acetyl-5-methoxytryptamine) is a molecule first
discovered and described in the pineal gland.1 It was classi-
cally considered to be exclusively produced by this structure
until years later when melatonin synthesizing enzymes were
found in several organs and structures.2 Among the huge
number of organs and cells producing melatonin, the eye
was one of the first organs discovered to synthesize melatonin,
first starting from the retina.2 Afterward, the attention was
attracted to several ocular structures and melatonin now is
known to be synthesized in the iris, ciliary body,3 crystalline
lens,4,5 and the lacrimal gland.6
In the eye, melatonin plays numerous functions. It has the
ability to accelerate corneal wound healing,7 it serves as an
antioxidant in the eye, and it protects the eye against oxidative
stress due to aging or diseases.8–10 Moreover, melatonin low-
ers intraocular pressure (IOP) and participates in the physiol-
ogy of the aqueous humor, as well as the pathophysiology of
glaucoma.11,12
Glaucoma is a multifactorial disease which results in
a progressive irreversible optic neuropathy and peripheral
visual field loss.13 It is the second leading cause of vision
loss14 and it is developed as a consequence of several risk
factors, the only controllable one being IOP.15 Glaucoma can
be controlled through different drugs aiming to lower IOP.
Nevertheless, apart from the commercially available
compounds, more substances such as melatonin and its ana-
logs rise as a possible therapeutic agent to lower IOP and
control glaucoma.12
Melatonin synthesis is controlled by light–darkness cycles
and this is specially relevant in the eye since it is the window
of the body to the outside. Several years ago, a photo pigment
named melanopsin was described in a small subclass of the
retinal ganglion cells. These studies showed that it participates
in a nonimage forming pathway since it was active and func-
tional in blind subjects and, moreover, in enucleated mice.16–
18 This photo pigment is responsible for photo-entrainment,
and its activation occurs by means of short wavelength light
(470–480 nm) leading to melatonin suppression.19
Evidences during the last three decades have indicated that
illumination, received by the eye, has an influence in many
human physiological and behavioral aspects.20,21 For instance,
light constricts the pupil, increases heart rate, body temperature,
and suppresses melatonin synthesis.22,23 Based on these changes
in the physiology carried out by light, several therapeutic appli-
cations have been developed.24 For example, light has been
shown to have antidepressant properties, specially for the treat-
ment of seasonal effective disorder,25,26 also, a proper timed light
exposure has been developed as a therapy for circadian rhythm
sleep disorders and circadian disruption due to jet lag, and finally
light has been used for depression treatment.27,28 On the other
hand, short wavelength light presents some serious harm to the
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eye, since it could lead to retinal cells damage.29,30 All these
studies and discoveries highlight the importance of light and,
consequently, melanopsin physiological role.
Recently, melanopsin has been described in the crystalline
lens epithelium of humans. This study has shown that epithe-
lial crystalline lens cells responded to light by modifying
melatonin levels. An increment in melatonin was observed
after hours of incubation in darkness, while under light con-
ditions, the synthesis of this substance was abolished. This
effect was confirmed to be regulated by melanopsin present in
the lens.31 Together with the fact that melatonin is present in
the aqueous humor, due to its synthesis in the ciliary body, we
believe that melatonin is also coming from neighbor tissues in
contact with the aqueous humor such as the crystalline lens.
In the current work, we show how melatonin present in the
aqueous humor can be modulated by means of yellow filters
in New Zealand white rabbits and how the presence of this
substance can modify IOP.
Material and methods
Animals
Male New Zealand white rabbits, weighing an average of
2.5 ± 0.5 kg, were used for this study. The animals were
kept in individual cages with free access to food and water.
The control and pharmacological groups were kept under
controlled 12 h day–night cycles, while a different group was
kept in cages enveloped with a yellow filter, though receiving
12 h day–night cycles. This study adhered to the ARVO
Statement for the Use of Animals in Opthalmic and Vision
Research, and also all animal care and experimental proce-
dures were carried out in accordance with the European
Communities Council Directive (86/609/EEC).
Experimental procedures
The effect of the yellow filter (465–480) as well as the pharma-
cological compounds which were tested measuring IOP were
carried out using a TonoVet contact tonometer supplied by
Tiolat Oy (Helsinki, Finland). All the measurements were per-
formed at the same time of the day, 10 am, in order to
minimize IOP variations. The TonoVet takes five consecutive
IOP measurements and calculate the mean of the value. At any
given time, IOP is measured three times and the values
obtained were transformed into mean ± s.e.m. For the experi-
ments using the yellow filter, IOP was measured once a week
during 1 month before taking them out of the filter to study the
possible change during the following month. For pharmacolo-
gical assays, two measurements were taken at 30 min interval
before any substance was added. IOP was measured at different
intervals of time depending on the experiment, and the sub-
stances were applied topically (20 µl) in a bilateral way.
For the filter group, 20 µl cocktail of luzindole (nonspecific
antagonist for melatonin receptors) and 4PPDOT (4-phenyl-
2-propionamidotetralin, MT2 specific antagonist), both pro-
vided from Tocris, Bristol, UK, were administered as eye
drops at final concentration of 100 µM. Experiments were
done after 3 weeks in yellow filter-covered cages. IOP
measurements were taken after 10, 30, 45, 60, 90, 120 min
of instillation.
For the control group, 20 µl of AA92593 (melanopsin
antagonist, prepared in PEG-400, DMSO, SML0865, Sigma,
St. Louis, Mo, USA) was used at a final concentration of
100 µM. IOP measurements were done at 20 min, 40 min,
1, 2, 3, 4, 5, and 6 h after applying the antagonist.
For the aqueous humor collection, rabbits were anesthetized
with a subcutaneous injection of a mixture of ketamine (7.5 mg/
kg, Imalgene 1000, Merial, Barcelona, Spain) and Domitor
(0.25 mg/mg, DOMTOR®, Orion Pharma, Espoo, Finland).
Aqueous humor (100 μl) was extracted with a syringe connected
with a 30-ga needle in the sacro-corneal limbus. Samples were
stored in −20°C until the time of the analysis.
Samples of the aqueous humor were processed for
HPLC (High Performance Liquid Chromatography) analysis
using the protocol described elsewhere.32 Briefly, samples were
submitted to a 98°C dry bath for 2 min before they were trans-
ferred to ice during 10 min, finally, the samples were centrifuged
to pellet proteins at 13,000 g for 10 min at 4°C before the
injection. In brief, the column was a Kromaphase C18 column
5.0 mm (25 cm in length, 0.4 cm inner diameter) (Scharlau,
Madrid, Spain). The systemwas equilibrated overnight with 40%
methanol and 60% H2O. Measurements were performed at
a flow rate of 0.8 ml/min fixing the detector at a wavelength of
244 nm. The chromatographic system for all the determinations
consisted of a 1515 Isocratic HPLC pump, a 2487 dual absor-
bance detector, and a Rheodyne injector, all managed by the
software Breeze from Waters (Milford, MA). Quantification
melatonin was performed by comparing the samples with the
corresponding external standard provided by Sigma.
Statistical analysis
Data represent the mean ± s.e.m of separate indicated number
of experiments for each case, and statistical significance was
calculated by ANOVA or Student t-test when necessary. All
the plots were obtained by GraphPad Prism (GraphPad
Software Inc., San Diego, CA).
Results
Effect of yellow filter on IOP
Recently, the presence of melanopsin and its effect on ATP
release have been demonstrates in New Zealand with rabbits.33
Rabbits maintained under the yellow filter presented
a significant reduction of IOP, this reduction was most appre-
ciated after 3 weeks under the yellow filter. IOP decreased up to
43.8 ± 7.8% (***p < 0.0001, n = 6) compared to the control
animals (Figure 1A). This effect was completely reversed
30 min after the topical application of both the selective and
nonselective melatonin receptor antagonists, 4PPDOT and
luzindole, respectively (Figure 1B). This is a clear indication
of the involvement of melatonin receptors in the hypotensive
effect observed by the use of this filter. When the rabbits were
placed under white light/darkness cycles, it resulted in
a gradual recovery of the IOP reaching values similar to the
control ones after 4 weeks (Figure 1A; ***p < 0.0001, n = 6).
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Involvement of melanopsin on light effect and melatonin
contribution
To confirm melanopsin involvement on light effect previously
described, we were able to block melanopsin by using its
selective antagonist AA92593 under white light condition.
Interestingly, inhibiting melanopsin under light condition
resulted in a similar behavior to the one obtained by the filter.
IOP dropped up to 32.7 ± 15.0% (***p < 0.0001, n = 6) 2 h
after the application of a single dose of melanopsin antagonist
compared to the control rabbits (Figure 1C).
A possible explanation for the changes observed on IOP
was the possible increase in melatonin levels in the aqueous
humor. As expected, melatonin levels have increased signifi-
cantly from 16.33 ± 4.50 ng/ml (before submitting rabbits to
yellow filter) to 39.04 ± 5.56 ng/ml (during the third week
under the yellow filter, ***p < 0.0001, n = 6) in the aqueous
humor. Control animals, those under normal white light,
showed melatonin levels of 16.50 ± 2.50 ng/ml, values which
did not change significantly during 8 weeks (17.14 ± 5.30 ng/
ml last week of the assay) (Figure 2).
Interestingly, the increment of melatonin levels in the
aqueous humor has returned to its normal values gradually
when the rabbits were moved from the yellow filter to
a normal white light/darkness cycle (Figure 2). They showed
16.80 ± 4.55 ng/ml of melatonin in the aqueous humor, this
reduction is significant compared to the highest concentration
found in the same animals after 3 weeks in the yellow filter
(***p < 0.0001, n = 6).
Discussion
The current work describes for the first time the effect of block-
ing short wavelength light over IOP. Submitting New Zealand
rabbits to a yellow filter environment resulted in a decrease of
IOP observed after 2 weeks. This effect was reversed by using
both, the selective and nonselective melatonin receptors antago-
nists, 4PPDOT and luzindole, respectively. Moreover, this indi-
cates the role of melanopsin in regulating melatonin synthesis in
the aqueous humor. From one hand, melatonin, present in the
aqueous humor, was significantly higher in the rabbits under
yellow filters compared to the control animals under white light.
On the other hand, blockingmelanopsin bymeans of its selective
antagonist AA92593 was able to decrease IOP in rabbits living
under normal light condition.
Figure 1. (A) Effect of yellow filter on rabbit intraocular pressure. Time course of yellow filter for 4 weeks followed by the recovery time in 12/12 h light darkness.
Hundred percent represents the intraocular pressure before starting the experiments (i.e., at t 0) and was equivalent to 8.70 ± 1.30 mm Hg. Values represent the
mean ± s.e.m (***p < 0.0001, n = 6) with respect to the control values. (B) Effect of the instillation of melatonin antagonists (luzindole + 4PPDOT) in rabbits after
3 weeks in yellow filter-covered cages compared to the control. This reduction of IOP due to the filter was completely reversed 30 min after the topical application of
both the selective and nonselective melatonin receptor antagonists. (C) Line graph confirming the implication of melanopsin receptor in IOP. Hundred micrometer of
melanopsin antagonist AA92593 resulted in a reduction of IOP after 2 h of topical instillation (***p < 0.0001, n = 6).
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These results are indicating a powerful effect of light mod-
ulating IOP values. Concerning the possible hypotensive effect
of the yellow filters, a study by Ichikawa and colleagues was
done to analyze changes in blood pressure and assess sleep
duration in patients before and after they underwent cataract
surgery and intraocular lens (IOL) implantation with yellow-
tinted lenses. Interestingly, these patients had a significant
decrease of cytosolic and diastolic blood pressure 1 month
after implanting the yellow-tinted IOL.34
The ability of blocking this decrease in IOP by means of
antagonizing melatonin receptors is highlighting that the
hypotensive effect is due to the direct binding of melatonin
to its membrane receptors. These receptors are present in
several structures in contact with the aqueous humor, and in
this sense, studies showed that melatonin receptor activation
in the nonpigmented ciliary body epithelial cells leads to
a reduction of Cl− efflux and hence lowering the IOP.35 This
is of great importance since it could open a possible compli-
ment way to increase efficient melatonin in the aqueous
humor as a novel way of drug delivery, by augmenting its
endogenous levels as previously suggested.36
Another melatonin producing structure in the eye is the
crystalline lens, where it is bathed also in the aqueous humor.37
A recent study discovered melanopsin presence in the lens, and
its ability to regulate melatonin secretion from the epithelial lens
cells.31 Although results in that study indicated an increment of
melatonin after 8 h of incubation in darkness that effect was
blocked by the melanopsin antagonist. In the present work, the
blockade of melanopsin by means of the antagonist AA92593
produced an increment in melatonin levels resulting in a drop of
IOP. This effect could be explained by the activation of the key
enzyme of melatonin synthesis, AANAT, since it can trigger
melatonin production in a very quick manner.38 Very recently,
it has been possible to demonstrate that a yellow filter can
modify the release of the nucleotide ATP from rabbit lenses.
Interestingly, either with the whole animal or with cultured
lenses, the blockade of melanopsin significantly reduced the
release of ATP.33 This is indicating that light, activating the
photopigment melanopsin, can induce the release of this nucleo-
tide. On the contrary, and as described in the present work, light
inhibits the synthesis of melatonin. Although the functions of
melatonin and ATP in the eye are different,39 the possibility of
modifying the presence of these substances by using a filter is
something relevant. It is possible by using filters to increase the
presence of melatonin and to decrease the release of ATP,33
therefore acting pharmacologically without using drugs but by
using the light as an agonist or antagonist.40
In summary, melanopsin photo pigment plays an indirect,
still important role on IOP modulation through the regulation
of melatonin production in the aqueous humor. The use of
yellow filters blocking blue light could be a novel approach to
reduce IOP and prevent the progression of glaucoma.
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